anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Postpancreatectomy hemorrhage (PPH) is a rare yet dreaded complication following pancreaticoduodenectomy (PD). This retrospective study aimed to explore a machine learning (ML) model for predicting PPH in PD patients.
METHODS: A total of 284 patients who underwent open PD at our institute were included in the analysis. To address the issue of imbalanced data, the adaptive synthetic sampling (ADASYN) technique was employed. The best-performing ML model was selected using the PyCaret library in Python and evaluated based on recall, precision, and F1 score metrics. In addition to assessing the model's performance on the test data, bootstrap validation (n = 1000) with the original dataset was conducted.
RESULTS: PPH occurred in 11 patients (3.9%), with a median onset time of 22 days postoperatively. These minority cases were oversampled to 85 using ADASYN. The extra trees classifier demonstrated superior performance with recall, precision, and F1 score of 0.967, 0.914, and 0.937, respectively. Both validation using the test data and bootstrap resampling consistently demonstrated recall, precision, and F1 score exceeding 0.9. The model identified the peak value of C-reactive protein during the first 7 postoperative days as the most significant feature, followed by the preoperative neutrophil-to-lymphocyte ratio.
CONCLUSIONS: This study highlights the potential of the ML approach to predict PPH occurrence following PD. Vigilance and early interventions guided by such model predictions could positively impact outcomes for high-risk patients.
The present invention provides compositions and methods for delivering therapeutic agents across a barrier. The composition includes a therapeutic agent (e.g., an antimicrobial agent, an antibiotic, or an anesthetic agent), a permeation enhancer that increases the flux of the therapeutic agent across the barrier, and a matrix forming agent. The matrix forming agent forms a gel for drug delivery at a suitable gelling temperature and rheology, and in some cases, the gelling temperature and rheology are not significantly altered from the gelling temperature and rheology of the composition without the permeation enhancer. The invention also provides matrix forming agents and compositions thereof. Such compositions are particularly useful for treating otitis media. Methods of treatment, methods of delivery, and kits for the compositions described herein are also provided.
PURPOSE: A composition for treating erectile dysfunction in a human male obtained from natural material such as Ginseng radix rubra extract powder, evening primrose oil and egg yolk oil is provided. Therefore, a food containing the composition is effective in the treatment of heart disease and prevention of adult disease and aging as well as erection promotion. CONSTITUTION: The composition comprises 10 to 70% by weight of Ginseng radix rubra extract powder, 10 to 70% by weight of evening primrose(Oenothera odorata Jacq.) oil and 10 to 70% by weight of egg yolk oil(an egg yolk oil of a wild duck) in a weight ratio of 1:1:1. The food contains 100 parts by weight of the composition, 0.5 to 10 parts by weight of bees wax, 0.5 to 10 parts by weight of soybean oil and 0.5 to 10 parts by weight of lecithin. The Ginseng radix rubra extract powder has a saponin content of 70kg/g or more and a solid content of 60% or more, the evening primrose contains 70% by weight of linoleic acid, 7.0% by weight of γ-linoleic acid and other fatty acids, and the egg yolk oil contains 95% by weight of linoleic acid, γ-linoleic acid and other fatty acids.
BACKGROUND: Most adults with sickle cell disease will experience a silent cerebral infarction (SCI) or overt stroke. Identifying patient subgroups with increased stroke incidence is important for future clinical trials focused on stroke prevention. Our 3-center prospective cohort study tested the primary hypothesis that adults with sickle cell disease and SCIs have a greater incidence of new stroke or SCI compared with those without SCI. A secondary aim focused on identifying additional risk factors for progressive infarcts, particularly traditional risk factors for stroke in adults.
METHODS AND RESULTS: This observational study included adults with sickle cell disease and no history of stroke. Magnetic resonance imaging scans of the brain completed at baseline and >1 year later were reviewed by 3 radiologists for baseline SCIs and new or progressive infarcts on follow-up magnetic resonance imaging. Stroke risk factors were abstracted from the medical chart. Time-to-event analysis was utilized for progressive infarcts. Median age was 24.1 years; 45.3% of 95 participants had SCIs on baseline magnetic resonance imaging. Progressive infarcts were present in 17 participants (17.9%), and the median follow-up was 2.1 years. Incidence of new infarcts was 11.95 per 100 patient-years (6.17-20.88) versus 3.74 per 100 patient-years (1.21-8.73) in those with versus without prior SCI. Multivariable Cox regression showed that baseline SCI predicts progressive infarcts (hazard ratio, 3.46 [95% CI, 1.05-11.39]; P=0.041); baseline hypertension was also associated with progressive infarcts (hazard ratio, 3.23 [95% CI, 1.16-9.51]; P=0.025).
CONCLUSIONS: Selecting individuals with SCIs and hypertension for stroke prevention trials in sickle cell disease may enrich the study population with those at highest risk for infarct recurrence.
Cohort 1 will include 3 periods. In Period 1 GSK3640254 will be administered (Treatment A). In Period 2 DRV/RTV will be administered (Treatment B). In Period 3 GSK3640254 (Treatment A) and DRV/RTV (Treatment B) will be administered.
FIELD: medicine, phthisiology. SUBSTANCE: invention can be used for treatment of sarcoidosis. Method involves carrying out plasmapheresis and blood lymphocytes are treated with prednisolon in the dose 300 mcg/ml or cyclosporin in the dose 10 mcg/ml of supernatant and the prepared concentrate is reinfused into blood stream of patient. Invention promotes to rapid onset of curative effect, to reduce dose of systemic corticosteroids or to exclude their from therapy treatment completely. EFFECT: improved method for treatment. 2 ex
Patients with endometriosis related chronic frequent pain and high pain intensity (≥ 4 according to Numeric Rating Scale, NRS) randomized to conventional analgesic treatment for 8 weeks. After 8 weeks the patients are treated with transcutaneous electrical nerve stimulation (TENS) during 16 weeks.
BACKGROUND: Kennedy disease (KD) is a slowly progressive lower motor neuron degenerative disease. The prevalence of KD is unknown in India.
AIM: To describe the phenotypic and laboratory features of an Indian cohort of KD patients.
METHODS: A retrospective study was done on seven genetically confirmed KD patients based on demographic, clinical and laboratory details.
RESULTS: Mean age at onset and presentation was 37 ± 11.9 and 44.6 ± 13.5 years respectively. Progressive asymmetric proximal and distal limb weakness was the commonest symptom (57.1%). All patients had motor symptoms along with non-specific symptoms such as cramps from the onset. Easy fatigability, decremental response along with ptosis were noted in two patients, which was a novel finding. Gynaecomastia and tongue wasting with fasciculations were universal findings. All five patients with nerve conduction studies showed sensorimotor neuropathy. Magnetic resonance imaging muscle done in two patients showed a prominent moth-eaten appearance in the thigh and posterior leg compartment in one patient. The mean cytosine-adenine-guanine repeats were 44 ± 3.7, and there was no association between age of onset or severity with repeat length. Only one patient required an assistive device for ambulation after 15 years of symptom onset.
CONCLUSIONS: This study showed phenotypic heterogeneity in the Indian cohort. The age of onset was earlier with a slowly progressive indolent course as compared with other ethnic cohorts. This highlights the importance of considering the KD diagnosis in patients with the indolent course and suspected ALS diagnosis even with ptosis and fatigability in an appropriate clinical context.
The invention relates to a device and method for generating an inspection report. The device for generating the inspection report comprises a report inputting unit, a context characteristic identifying unit, a processing unit and an auxiliary inputting unit. The report inputting unit is used for receiving the input inspection report from a user and used for displaying content of the inspection report currently input. The context characteristic identifying unit is used for identifying one or more context characteristics from the content of the inspection report currently input in a real-time mode. The processing unit is used for processing inspection data of an object based on the one or more identified context characteristics. The auxiliary inputting unit is configured and used for enabling the report inputting unit to display a list of items of the inspection data after processing of the processing unit when specific user inputting is detected so that the user can select; when the user selects the items in the list, the processed inspection data corresponding to the selected items are inserted into the inspection report.
Participants attend support group sessions over 1-1.5 hours once weekly for 10 weeks. The sessions include facilitated discussions among participants about the following topics: stress management and emotional coping strategies, nutrition and physical activity, sexuality and body image, medical advocacy, self-care and social support. Participants receive a binder in which the rationale for each topic, techniques learned, and activities completed during each session will be summarized and are shown a Chair-robics DVD.
Patients receive fermented wheat germ PO daily starting 3 days prior to the start of standard of care checkpoint inhibitor therapy on days 1-56 for 8 weeks. Patients undergo blood sample collection during screening, on days 1, 4, 15, 43 and at the end of treatment visit. Patients undergo stool sample collection during screening, day 1, 4 and at the end of treatment visit.
Restenosis following percutaneous revascularization is a major challenge in patients with insulin resistance and diabetes. Currently, the vascular effects of insulin are not fully understood. In vitro, insulin's effects on endothelial cells (ECs) are beneficial, whereas on vascular smooth muscle cells (SMCs), they are mitogenic. We previously demonstrated a suppressive effect of insulin on neointimal growth under insulin-sensitive conditions that was abolished in insulin-resistant conditions. Here, we aimed to determine the cell-specific effects of insulin on neointimal growth in a model of restenosis under insulin-sensitive and insulin-resistant conditions. Vascular cell-specific insulin receptor (IR)-deficient mice were fed a low-fat diet (LFD) or a high-fat, high-sucrose diet (HFSD) and implanted with an insulin pellet or vehicle prior to femoral artery wire injury. In insulin-sensitive conditions, insulin decreased neointimal growth only in controls. However, under insulin-resistant conditions, insulin had no effect in either control, EC-specific or SMC-specific IR-deficient mice. These data demonstrate that EC and SMC IRs are required for the anti-restenotic effect of insulin in insulin-sensitive conditions and that, in insulin resistance, insulin has no adverse effect on vascular SMCs in vivo.
BACKGROUND: Lymphatic leakage is one of the postoperative complications of neuroblastoma. The purpose of this study is to summarize the clinical characteristics and risk factors of lymphatic leakage and try to find effective prevention and treatment measures.
METHODS: A retrospective study included 186 children with abdominal neuroblastoma, including 32 children of lymphatic leakage and 154 children of non-lymphatic leakage. The clinical information, surgical data, postoperative abdominal drainage, treatment of lymphatic leakage and prognosis of the two groups were collected and analyzed.
RESULTS: The incidence of lymphatic leakage in this cohort was 14% (32 children). Through univariate analysis of lymphatic leakage group and non-lymphatic leakage group, we found that lymphatic leakage increased the complications, prolonged the time of abdominal drainage and hospitalization, and delayed postoperative chemotherapy (p < 0.05). In this cohort, the median follow-up time was 46 (95% CI: 44-48) months. The follow-up data of 7 children were partially missing. 147 children survived, of which 23 had tumor recurrence (5 children recurred in the surgical area). 37 children died, of which 32 had tumor recurrence (9 children recurred in the operation area). In univariate analysis, there was no statistical difference in overall survival (p = 0.21) and event-free survival (p = 0.057) between lymphatic leakage group and non-lymphatic leakage group, while 3-year cumulative incidence of local progression was higher in lymphatic leakage group (p = 0.015). However, through multivariate analysis, we found that lymphatic leakage did not affect event-free survival, overall survival and cumulative incidence of local progression in children with neuroblastoma. Resection of 5 or more lymphatic regions was an independent risk factor for lymphatic leakage after neuroblastoma surgery. All 32 children with lymphatic leakage were cured by conservative treatment without surgery. Of these, 75% (24/32) children were cured by fat-free diet or observation, 25% (8/32) children were cured by total parenteral nutrition. The median drain output at diagnosis in total parenteral nutrition group was higher than that in non-total parenteral nutrition group (p < 0.001). The cut-off value was 17.2 ml/kg/day.
CONCLUSIONS: Lymphatic leakage does not affect the prognosis of children with neuroblastoma, but long-term drain output caused by lymphatic leakage will still adversely affect postoperative complications and follow-up treatment, which requires attention and active treatment measures. More attention should be paid to the children with 5 or more lymphatic regions resection, and the injured lymphatic vessels should be actively found and ligated after tumor resection to reduce the postoperative lymphatic leakage. Early application of total parenteral nutrition is recommended for those who have drain output at diagnosis of greater than 17.2 ml/kg/day.
LEVEL OF EVIDENCE: Level III, Treatment study (Retrospective comparative study).
A cosmetic composition is provided which can reduce or eliminate cellulite or fat build-ups on a human body. The composition includes at least one rubefacient, at least one oil soluble plant extract, and at least one volatile organo polysiloxane. The ingredients are contained in an oil base which can be of vegetable or animal origin, and mineral oil or even a synthetic oil or any mixture of these oils. The rubefacient substance is generally present in the compound in concentrations ranging from between 0.05 and 5% by weight. The substance which can be used as a rubefacient include capsicum extracts; nicotinic acid salts; nicotinic acid esters; and nicotinyl alcohols. The oil soluble plant extract can be a mixture of ivy, rosemary, ginseng, sage, arnica, Saint Johns wort, marigold, ruscus, ulmaria, orthosiphon and algae in any combination. The organo polysiloxane is generally in concentrations ranging between 10 and 85% by weight.
Pain intensity is the most commonly used outcome domain in pain clinical trials. To minimize the chances of type II error (ie, concluding that a treatment does not have beneficial effects, when in fact it does), the measure of pain intensity used should be sensitive to changes produced by effective pain treatments. Here we sought to identify the combination of pain intensity ratings that would balance the need for reliability and validity against the need to minimize assessment burden. We conducted secondary analyses using data from a completed 4-arm clinical trial of psychological pain treatments (N = 164 adults). Current, worst, least, and average pain intensity in the past 24 hours were assessed 4 times before and after treatment using 0 to 10 numerical rating scale-11. We created a variety of composite scores using these ratings and evaluated their reliability (Cronbach's alphas) and validity (ie, associations with a gold standard score created by averaging 16 ratings and sensitivity for detecting between-group differences in treatment efficacy). We found that for each measure, reliability increased as the number of ratings used to create the measures increased and that ratings from 3 or more days were needed to have adequately strong associations with the gold standard. Regarding sensitivity, the findings suggest that composite scores made up of ratings from 4 days are needed to maximize the chances of detecting treatment effects, especially with smaller sample sizes. In conclusion, using data from 3 or 4 days of assessment may be the best practice. PERSPECTIVE: Composite scores made up of at least 3 days of pain ratings appear to be needed to maximize reliability and validity while minimizing the assessment burden. TRIAL REGISTRATION: clinicaltrials.gov NCT01800604.
The agent with antistress, anxiolytic and antidepressant activity and a composition based on it. The invention relates to the field of pharmaceutics, particularly to chemical compounds based on lithium salts, namely to substances with antistress, anxiolytic and antidepressant activity and can be used in medicine, veterinary medicine, and the pharmaceutical industry. The invention discovers the possibility of using lithium ascorbate as an agent with antistress, anxiolytic and antidepressant activity. The claimed composition with antistress, anxiolytic and antidepressant activity, including a lithium salt, contains pyridoxine hydrochloride, thiamine mononitrate and lithium ascorbate as a lithium salt. The use of lithium ascorbate as an agent with antistress, anxiolytic and antidepressant action and the composition based on it, enables to expand the assortment of the agents for indicated administration. At the same time, the claimed agents have low toxicity and high efficacy.
The monarch drug wine is mixed with adjuvant herb wine at a volume ratio of 1:2 to prepare an chinese herbal medicine health wine. Said monarch drug wine is taken by Maifan Stone, actinolite, chloranthus holostegius, panax notoginseng, Ban Fenghe, Sargentodoxa cuneata, dadabusi, Sabia schwnanmana, Gastrodia elata, laohuxu, gouluoteng,  Sarcandra glabra, houzijiang infused with 40-50degree pure rice wine. Said adjuvant herb wine is taken by Eucommia ulmoides, Dipacus asperoides, zhuangyangcao, Native Copper, Gynuradivaricata, miltiorrhiza, Cassia obtusifolia, Rubus lambertianus, Cortex Ilecis Rotundae, Ardisia crenata, roots of madder, Glycyrrhiza infused with pure rice wine. The preparation method include the follow  steps: feed preparation, weighing respectively component drugs at ratio in monarch drug and adjuvant herb, infusing respectively monarch drug and adjuvant herb, preparing package and so on. Said wine do not contain any chemical substance, Essence, pigment. It has the effects of supplementing qi blood, regulating yin yang, activating blood and removing stasis, anti-inflammatory and analgesic, strengthening tendons and bones, promoting the body resistance and eliminating pathogenic factors. The method is simple and reasonable.
The method involves production of Fra e 1 by recombinant technology in yeast Pichia pastoris, which implies the use of nucleotide sequences obtained by the mutagenesis. A major allergen is isolated, purified and characterized from fraxinus excelsior pollen, and is recognized by 65 percent of patients allergic to the biological source. The allergen is cloned and expressed in the recombinant deoxyribonucleic acid that encodes the Fra e 1 allergen of ash pollen. The recombinant protein is produced in yeast. The resulting fragments contain an epitope. An independent claim is also included for a recombinant variant of fraxinus excelsior ash pollen allergen, Fra e 1.
Acute myocardial infarction (AMI), characterized by high incidence and mortality rates, poses a significant public health threat. Reperfusion therapy, though the preferred treatment for AMI, often exacerbates cardiac damage, leading to myocardial ischemia/reperfusion injury (MI/RI). Consequently, the development of strategies to reduce MI/RI is an urgent priority in cardiovascular therapy. Chinese medicine, recognized for its multi-component, multi-pathway, and multi-target capabilities, provides a novel approach for alleviating MI/RI. A key area of interest is the nuclear factor E2-related factor 2 (Nrf2)/heme oxygenase-1 (HO-1) pathway. This pathway is instrumental in regulating inflammatory responses, oxidative stress, apoptosis, endoplasmic reticulum stress, and ferroptosis in MI/RI. This paper presents a comprehensive overview of the Nrf2/HO-1 signaling pathway's structure and its influence on MI/RI. Additionally, it reviews the latest research on leveraging Chinese medicine to modulate the Nrf2/HO-1 pathway in MI/RI treatment.
BACKGROUND: Stroke is a leading cause of disability, especially due to an increased fall risk and postural instability. The objective of this study was to analyze the impact of motor impairment in the hemiparetic UE on static balance in standing, in subject with chronic stroke.
METHODS: Seventy adults with chronic stroke, capable of independent standing and walking, participated in this cross-sectional study. The exclusion criteria included vestibular, cerebellar, or posterior cord lesions. The participants were classified based on their UE impairment using the Fugl-Meyer Assessment of Motor Recovery after Stroke (FMA-UE). A posturographic evaluation (mCTSIB) was performed in the standing position to analyze the center of pressure (COP) displacement in the mediolateral (ML) and anteroposterior (AP) axes and its mean speed with eyes open (OE) and closed (EC) on stable and unstable surfaces.
RESULTS: A strong and significant correlation (r = -0.53; p < 0.001) was observed between the mediolateral (ML) center of pressure (COP) oscillation and the FMA-UE, which was particularly strong with eyes closed [r(EO) = 0.5; r(EC) = 0.54]. The results of the multiple linear regression analysis indicated that the ML oscillation is influenced significantly by the FMA-Motor, and specifically by the sections on UE, wrist, coordination/speed, and sensation.
CONCLUSIONS: The hemiparetic UE motor capacity is strongly related to the ML COP oscillation during standing in individuals with chronic stroke, with a lower motor capacity associated with a greater instability. Understanding these relationships underpins the interventions to improve balance and reduce falls in people who have had a stroke.
Minocin (minocycline) for Injection was supplied as a sterile lyophilized powder in single-use 10-milliliter (mL) glass vials. Each vial contained 108 milligrams (mg) of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort received one of the following dosages of Minocin (minocycline) for Injection: 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 600 mg. Within each cohort, participants received a single dose on Day 1, followed by 7 days of multiple doses (Days 4 to 10, given every 12 hours), followed by a single dose on Day 11.